People news: Seattle Genetics, Ligand Pharmaceuticals and CyDex Pharmaceuticals

Share this article:

Seattle Genetics hired Natasha Hernday as VP, corporate development. She comes from Amgen, where was a senior member of the mergers and acquisitions team for about seven years, followed by two years building and leading Amgen's out-licensing efforts.

Ligand Pharmaceuticals hired Matthew Foehr to the newly created position of EVP and COO. He will primarily be responsible for managing the operations and strategic expansion of CyDex Pharmaceuticals, a specialty pharma company acquired by Ligand in January and overseeing Ligand's R&D programs. Foehr has more than 17 years of experience managing global R&D programs. Most recently he was VP and head of consumer dermatology R&D, as well as acting chief scientific officer of dermatology, in the Stiefel division of GlaxoSmithKline.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.